Product Information
51143-1-AP targets Vpr in WB, ELISA applications and shows reactivity with immunodeficiency virus 1 samples.
| Tested Reactivity | immunodeficiency virus 1 |
| Cited Reactivity | human, virus |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
CatNo: Ag0718 Product name: Recombinant Vpr protein Source: e coli.-derived, PGEX-4T Tag: GST Domain: 1-96 aa of NP_057852 Sequence: MEQAPEDQGPQREPHNEWTLELLEELKNEAVRHFPRIWLHGLGQHIYETYGDTWAGVEAIIRILQQLLFIHFRIGCRHSRIGVTRQRRARNGASR Predict reactive species |
| Full Name | Vpr |
| Calculated Molecular Weight | 11 kDa |
| GenBank Accession Number | NP_057852 |
| Gene Symbol | |
| Gene ID (NCBI) | |
| RRID | AB_10695191 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
This antibody recognize the VPR gene of Human immunodeficiency virus 1.
Publications
What published studies show
The Vpr Polyclonal antibody (catalog 51143-1-AP) has 17 total citations. It is published across leading journals including Nature Communications, PNAS, Cell Reports, PLoS Biology, mBio, PLoS Pathogens, iScience, Journal of Virology, Retrovirology, Journal of Biological Chemistry, AIDS, and bioRxiv. The research fields covered center on HIV-1 virology, including Vpr-mediated host protein degradation, epigenetic remodeling, DNA damage response and NF-κB signaling, latent infection reactivation, viral integration/replication, and host restriction factor mechanisms (e.g., APOBEC3G, IRF3, RIG-I). Most applications use Western blotting of human cell samples.
| Species | Application | Title |
|---|---|---|
Nat Commun HIV reprograms host m 6 Am RNA methylome by viral Vpr protein-mediated degradation of PCIF1 | ||
Proc Natl Acad Sci U S A CHAF1A/B mediate silencing of unintegrated HIV-1 DNAs early in infection. | ||
Cell Rep Promiscuous Targeting of Cellular Proteins by Vpr Drives Systems-Level Proteomic Remodeling in HIV-1 Infection. | ||
PLoS Biol DNA damage induced by HIV-1 Vpr triggers epigenetic remodeling and transcriptional programs to enhance virus transcription and latency reactivation. | ||
mBio Reversal of Epigenetic Silencing Allows Robust HIV-1 Replication in the Absence of Integrase Function. | ||
mBio HIV-1 Vpr-induced DNA damage activates NF-κB through ATM-NEMO independent of cell cycle arrest |
